PPM1D and breast neoplasm: Moreover, we extended the analysis of copy number amplification of ARHGEF11 and PPM1D to a cohort of breast tumors (4563 cases)43–46,55,56 using cBioportal47 (http://www.cbioportal.org) and revealed amplification of ARHGEF11 and PPM1D in 14.27% and 9.21% of patients, respectively.